- Home
- TNON vs APVO Comparison
TNON vs APVO Comparison
Compare TNON & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- APVO
- Stock Information
- Founded
- TNON 2012
- APVO 2016
- Country
- TNON United States
- APVO United States
- Employees
- TNON N/A
- APVO N/A
- Industry
- TNON Medical Specialities
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- APVO Health Care
- Exchange
- TNON Nasdaq
- APVO Nasdaq
- Market Cap
- TNON 3.2M
- APVO 3.3M
- IPO Year
- TNON 2022
- APVO N/A
- Fundamental
- Price
- TNON $1.17
- APVO $0.67
- Analyst Decision
- TNON Strong Buy
- APVO Strong Buy
- Analyst Count
- TNON 3
- APVO 1
- Target Price
- TNON $11.67
- APVO $296.00
- AVG Volume (30 Days)
- TNON 1.1M
- APVO 8.7M
- Earning Date
- TNON 05-13-2025
- APVO 05-07-2025
- Dividend Yield
- TNON N/A
- APVO N/A
- EPS Growth
- TNON N/A
- APVO N/A
- EPS
- TNON N/A
- APVO N/A
- Revenue
- TNON $3,277,000.00
- APVO N/A
- Revenue This Year
- TNON $118.16
- APVO N/A
- Revenue Next Year
- TNON $14.25
- APVO N/A
- P/E Ratio
- TNON N/A
- APVO N/A
- Revenue Growth
- TNON 11.92
- APVO N/A
- 52 Week Low
- TNON $0.91
- APVO $0.60
- 52 Week High
- TNON $15.79
- APVO $51.06
- Technical
- Relative Strength Index (RSI)
- TNON 46.02
- APVO 30.74
- Support Level
- TNON $1.06
- APVO $0.60
- Resistance Level
- TNON $1.19
- APVO $0.80
- Average True Range (ATR)
- TNON 0.11
- APVO 0.19
- MACD
- TNON -0.01
- APVO 0.03
- Stochastic Oscillator
- TNON 51.67
- APVO 6.97
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants, and 3) SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.